

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-43. (Cancelled)

44. (Currently Amended) A method of treating an immunological disorder in a subject, the method comprising administering to the subject an effective amount of a composition comprising ~~(a) an antagonist antibody or antigen-binding fragment thereof that binds to KIM-1, or (b) a polypeptide comprising a KIM-1 immunoglobulin domain,~~ wherein the immunological disorder is myasthenia gravis, autoimmune hemolytic anemia, Chagas disease, Graves disease, idiopathic thrombocytopenia purpura, Wegener's granulomatosis, polyarteritis nodosa, rapidly progressive crescentic glomerulonephritis, or graft-versus-host disease.

45. (Currently Amended) A method of treating an immunological disorder in a subject, the method comprising administering to the subject an effective amount of a composition comprising ~~(a) an antagonist antibody or antigen-binding fragment thereof that binds to KIM-1, or (b) a polypeptide comprising a KIM-1 immunoglobulin domain,~~ wherein the immunological disorder is arthritis or an inflammatory bowel disease.

46. (Cancelled)

47. (Currently Amended) The method of claim ~~45-46~~, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, monoclonal antibody, humanized antibody, fully human antibody, chimeric antibody, single-chain antibody, diabody, Fab fragment, Fab'

fragment, F(ab')₂ fragment, Fv fragment, Fd fragment, dAb fragment, or complementarity determining region-containing fragment.

48-54. (Cancelled)

55. (New) The method of claim 45, wherein the immunological disorder is an inflammatory bowel disease.

56. (New) The method of claim 55, wherein the inflammatory bowel disease is Crohn's disease, ulcerative colitis, or ileitis.

57. (New) The method of claim 44, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, monoclonal antibody, humanized antibody, fully human antibody, chimeric antibody, single-chain antibody, diabody, Fab fragment, Fab' fragment, F(ab')₂ fragment, Fv fragment, Fd fragment, dAb fragment, or complementarity determining region-containing fragment.

58. (New) The method of claim 55, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, monoclonal antibody, humanized antibody, fully human antibody, chimeric antibody, single-chain antibody, diabody, Fab fragment, Fab' fragment, F(ab')₂ fragment, Fv fragment, Fd fragment, dAb fragment, or complementarity determining region-containing fragment.

59. (New) The method of claim 56, wherein the antibody or antigen-binding fragment thereof is a polyclonal antibody, monoclonal antibody, humanized antibody, fully human antibody, chimeric antibody, single-chain antibody, diabody, Fab fragment, Fab' fragment, F(ab')₂ fragment, Fv fragment, Fd fragment, dAb fragment, or complementarity determining region-containing fragment.